Bio-Rad Laboratories, Inc. BIO is well-poised to grow in the upcoming quarters, courtesy of its strong traction in the QX600 Droplet Digital PCR (ddPCR) platform. Demand for its quality control and ...
Bio-Rad Laboratories, Inc. (NYSE:BIO) reported better-than-expected second-quarter financial results on Thursday. Bio-Rad Laboratories reported quarterly earnings of $2.61 per share which beat the ...
The average one-year price target for Bio-Rad Laboratories (NYSE:BIO) has been revised to $362.10 / share. This is an increase of 14.15% from the prior estimate of $317.22 dated November 7, 2025. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results